<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940962</url>
  </required_header>
  <id_info>
    <org_study_id>VERGES 2020</org_study_id>
    <nct_id>NCT04940962</nct_id>
  </id_info>
  <brief_title>Translational Study Using Human Abdominal Adipose Tissue Biopsies to Investigate the Role of Cannabinoid Receptor 1 (CB1) in Controlling Endocannabinoid and Adipokine Secretion</brief_title>
  <acronym>ENDOCATA</acronym>
  <official_title>Translational Study Using Human Abdominal Adipose Tissue Biopsies to Investigate the Role of Cannabinoid Receptor 1 (CB1) in Controlling Endocannabinoid and Adipokine Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abdominal obesity and type 2 diabetes are associated with the hyperactivation of the&#xD;
      endocannabinoid system. Several animal and human studies indicate that circulating&#xD;
      endocannabinoid (EC) levels are correlated with body fat. Thus, adipose tissue, which&#xD;
      possesses the enzymatic machinery for the synthesis of ECs, could be the main producer of&#xD;
      plasma ECs.&#xD;
&#xD;
      Today, it is clearly established that stimulation of the endocannabinoid system, via&#xD;
      activation of cannabinoid receptor 1 (CB1s) located in the brain, leads to increased food&#xD;
      intake and weight gain. Moreover, peripheral CB1s present in organs such as the liver,&#xD;
      muscles and adipose tissue are involved in the establishment of metabolic deregulations&#xD;
      linked to obesity (steatosis, insulin resistance, dyslipidemia).&#xD;
&#xD;
      Thus, ECs produced by adipose tissue could play a key role in the regulation of&#xD;
      carbohydrate-lipid homeostasis through their autocrine or paracrine actions by activating&#xD;
      central and peripheral CB1s. Therefore, the objective of this study is to:&#xD;
&#xD;
        1. clarify whether obesity, associated or not with diabetes, leads to an overproduction of&#xD;
           ECs (specifying which ones) by visceral or subcutaneous adipose tissue&#xD;
&#xD;
        2. to determine whether blocking CB1s with new peripherally acting antagonists can lead to&#xD;
           a reduction in the production of ECs by adipose tissue.&#xD;
&#xD;
      This study will also provide an opportunity to evaluate the production of adipokines and&#xD;
      cytokines involved in the control of energy homeostasis under the different experimental&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kinetics of the appearance of endocannabinoids produced by visceral adipose tissue explants in culture medium estimated by the area under the curve in obese subjects and in controls.</measure>
    <time_frame>12 hours</time_frame>
    <description>The assay will be performed using a technique of liquide chromatography coupled to a mass spectrometer.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Diabete Type 2</condition>
  <condition>Abdominal Obesity</condition>
  <arm_group>
    <arm_group_label>Non-diabetic obese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic obese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Witnesses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sampling of adipose tissue</intervention_name>
    <description>Removal of less than 1 cm3 of adipose tissue during visceral surgery</description>
    <arm_group_label>Diabetic obese</arm_group_label>
    <arm_group_label>Non-diabetic obese</arm_group_label>
    <arm_group_label>Witnesses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Controls:&#xD;
&#xD;
          -  male between the ages of 18 and 70&#xD;
&#xD;
          -  gave oral consent&#xD;
&#xD;
          -  to undergo visceral surgery&#xD;
&#xD;
        Non-diabetic obese subjects:&#xD;
&#xD;
          -  male 18 to 70 years of age&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  gave oral consent&#xD;
&#xD;
          -  to undergo visceral surgery&#xD;
&#xD;
        Obese diabetic subjects:&#xD;
&#xD;
          -  male aged 18 to 70 years&#xD;
&#xD;
          -  type 2 diabetic not treated with Insulin or GLP-1 agonist&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  gave oral consent&#xD;
&#xD;
          -  to undergo visceral surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Controls:&#xD;
&#xD;
          -  Person not covered by national health insurance.&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  associated condition: cancer, chronic inflammatory diseases&#xD;
&#xD;
          -  protected adult&#xD;
&#xD;
        Non-diabetic obese subjects:&#xD;
&#xD;
          -  Person not covered by national health insurance&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  associated condition: cancer, chronic inflammatory diseases,&#xD;
&#xD;
          -  protected adult&#xD;
&#xD;
        Obese diabetic subjects:&#xD;
&#xD;
          -  Person not covered by national health insurance&#xD;
&#xD;
          -  associated condition: cancer, chronic inflammatory diseases,&#xD;
&#xD;
          -  type 1 diabetes&#xD;
&#xD;
          -  secondary diabetes&#xD;
&#xD;
          -  protected adult&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pablo ORTEGA DEBALLON</last_name>
    <phone>03.80.29.37.47</phone>
    <email>pablo.ortega-deballon@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle SIMONEAU</last_name>
      <phone>0380293332</phone>
      <email>isabelle.simoneau@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Abdominal</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

